$1.42
Today
as of Sep 4, 16:45 ET
Last 30 days
Recent Press Releases & News
Acurx Pharmaceuticals Inc (ACXP) (Q2 2026) Earnings Call Highlights: FDA Signals Potential ...
Acurx Pharmaceuticals Receives FDA Conditional Acceptance and USPTO Trademark Allowance for the Company's Brand Name for Ibezapolstat
Acurx Pharmaceuticals, Inc. Q2 2026 Earnings Call Summary
Overview
52-week range
$1.31
$8.34
2% of range
Avg surprise (last 2)
+0.2%
Avg reaction (last 2)
+7.0%
100% positive
Earnings trends
EPS — actual vs estimate
Actual Estimate
Revenue vs Net Income
Revenue Net income
Earnings history
| Date | Period | Actual EPS | Est | Surprise | YoY %Δ | Day react | Source |
|---|---|---|---|---|---|---|---|
| Tue Jun 30, 2026 | Jun 2026 | $-0.53 | — | — | — | — | financials |
| Mon May 11, 2026 | Mar/2026 | $-0.62 | $-0.59 | -5.1% | -463.6% | +4.3% | earnings |
| Tue Sep 30, 2025 | Sep 2025 | $-1.23 | — | — | — | — | financials |
| Mon Aug 11, 2025 | Jun/2025 | $-1.89 | $2.00 | +5.5% | — | — | earnings |
| Mon May 12, 2025 | Mar/2025 | $-0.11 | — | — | — | +9.7% | earnings |
| Mon Sep 30, 2024 | Sep 2024 | $-3.45 | — | — | — | — | financials |
| Sun Jun 30, 2024 | Jun 2024 | $-5.21 | — | — | — | — | financials |
| Sun Mar 31, 2024 | Mar 2024 | $-0.28 | — | — | — | — | financials |
| Sat Sep 30, 2023 | Sep 2023 | $-0.24 | — | — | — | — | financials |
| Fri Jun 30, 2023 | Jun 2023 | $-0.28 | — | — | — | — | financials |
| Fri Mar 31, 2023 | Mar 2023 | $-0.25 | — | — | — | — | financials |
Financials
Income statement (quarterly)
| Metric | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | — | — | — | — |
| Cost of revenue | — | — | — | — | — | — | — | — |
| Gross profit | — | — | — | — | — | — | — | — |
| Operating income | $-2M | $-2M | — | $-2M | $-2M | $-2M | — | $-3M |
| Net income | $-2M | $-2M | — | $-2M | $-2M | $-2M | — | $-3M |
| EPS (diluted) | $-0.53 | $-0.62 | — | $-1.23 | $-1.89 | $-2.15 | — | $-3.45 |
Balance sheet (quarterly)
| Metric | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 |
|---|---|---|---|---|---|---|---|---|
| Cash & equivalents | $11M | $9M | $8M | $6M | $6M | $5M | — | $6M |
| Inventory | — | — | — | — | — | — | — | — |
| Total current assets | — | — | — | — | $6M | $5M | $4M | $6M |
| Total assets | $11M | $10M | $8M | $6M | — | — | $4M | — |
| Long-term debt | — | — | — | — | — | — | — | — |
| Total liabilities | $3M | $3M | $2M | $2M | $3M | $2M | $3M | $3M |
| Total equity | $8M | $7M | $5M | $4M | $4M | $2M | $615,121 | $3M |
Implied volatility — last 90 days
No IV snapshots yet for ACXP.
IV is captured twice daily (9:15 AM & 4:30 PM ET) for tickers with upcoming earnings. Comes online automatically once the next options refresh runs.